renal cell carcinoma

Merck’s Welireg Clears Phase III Primary Endpoint in Renal Cell Carcinoma
Merck’s Welireg Clears Phase III Primary Endpoint in Renal Cell Carcinoma
BioSpace
Merck
Welireg
renal cell carcinoma
clinical trials
Flag link:
Merck and Eisai tease results for renal carcinoma treatment
Merck and Eisai tease results for renal carcinoma treatment
Clinical Trials Arena
Merck
Eisai
ASCO 2023
Lenvima
Keytruda
renal cell carcinoma
Flag link:
Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure
Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure
BioSpace
Roche
Exelixis
renal cell carcinoma
Tecentriq
Cabometyx
clinical trials
Flag link:
BMS and Nektar Shutter Combination Cancer Development Program
BMS and Nektar Shutter Combination Cancer Development Program
BioSpace
Bristol Myers Squibb
Nektar Therapeutics
bladder cancer
renal cell carcinoma
bempegaldesleukin
Flag link:
Merck's Keytruda scores first win in adjuvant kidney cancer, giving it a leg up on checkpoint inhibitor rivals
Merck's Keytruda scores first win in adjuvant kidney cancer, giving it a leg up on checkpoint inhibitor rivals
Endpoints
Merck
Keytruda
adjuvant immunotherapy
renal cell carcinoma
Flag link:
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
BioSpace
Merck
Keytruda
advanced renal cell carcinoma
renal cell carcinoma
Eisai
Lemvima
FDA
Flag link:
Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use
Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use
Fierce Pharma
Merck
Keytruda
renal cell carcinoma
kidney cancer
clinical trials
Flag link:
Merck wins priority review for rare carcinoma drug belzutifan, the centerpiece of $1B+ Peloton buyout
Merck wins priority review for rare carcinoma drug belzutifan, the centerpiece of $1B+ Peloton buyout
Endpoints
Merck
Peloton Therapeutics
belzutifan
M&A
PT2977
renal cell carcinoma
priority review
FDA
Flag link:
Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer
Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer
BioSpace
Merck
ASCO GU
Keytruda
Eisai
Lenvima
renal cell carcinoma
Flag link:
Calithera flunks phase 2 cancer trial, axes 35% of staff
Calithera flunks phase 2 cancer trial, axes 35% of staff
Fierce Biotech
Calithera Biosciences
clinical trials
telaglenastat
renal cell carcinoma
layoffs
Flag link:
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Yahoo/Zacks.com
Exelixis
Cabometyx
FDA
kidney cancer
renal cell carcinoma
Bristol-Myers Squibb
Opdivo
Flag link:
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Endpoints
Bristol-Myers Squibb
Opdivo
Exelixis
Cabometyx
renal cell carcinoma
kidney cancer
clinical trials
Flag link:
After digging through discards, biotech startup is making a $45M bet it can fix a failed cancer therapy
After digging through discards, biotech startup is making a $45M bet it can fix a failed cancer therapy
Endpoints
Active Biotech
naptumomab
renal cell carcinoma
NeoTX
Flag link:
Opdivo delivers superior five-year survival results in renal cell carcinoma
Opdivo delivers superior five-year survival results in renal cell carcinoma
Pharmaceutical Business Review
Bristol-Myers Squibb
Opdivo
clinical trials
renal cell carcinoma
Flag link:
AstraZeneca dumps phase 3 renal cell carcinoma program
AstraZeneca dumps phase 3 renal cell carcinoma program
Fierce Biotech
AstraZeneca
savolitinib
renal cell carcinoma
Flag link:
Renal Cell Carcinoma Space in Focus: Some Key Developments
Renal Cell Carcinoma Space in Focus: Some Key Developments
Yahoo/Zacks.com
renal cell carcinoma
kidney cancer
Exelixis
Roche
Merck
Aveo Oncology
Flag link:
Xynomic Starts Ph III Trial of Abexinostat in Renal Cell Carcinoma
Xynomic Starts Ph III Trial of Abexinostat in Renal Cell Carcinoma
CP Wire
Xynomic
Abexinostat
renal cell carcinoma
Flag link:
Xynomic Starts Ph III Trial of Abexinostat in Renal Cell Carcinoma
Xynomic
Abexinostat
renal cell carcinoma
Flag link:
Keytruda-Inlyta combo under Priority Review for first-line RCC
Keytruda-Inlyta combo under Priority Review for first-line RCC
BioCentury
Merck
Keytruda
Inlyta
renal cell carcinoma
FDA
priority review
Flag link:
Asco-GU – Bristol’s renal cancer lead looks to be short-lived
Asco-GU – Bristol’s renal cancer lead looks to be short-lived
EP Vantage
renal cell carcinoma
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
clinical trials
Sutent
Flag link:

Pages